【摘 要】
：
Radiotherapy is commonly used to treat thoracic malignancies but often causes severe lung injury.Currently there are no effective protective strategies against radiation-induced lung injury (RILI).Thi
【机 构】
：
Cancer Center, Union Hospital, Tongji Medical College,Huazhong University of Science and Technology
论文部分内容阅读
Radiotherapy is commonly used to treat thoracic malignancies but often causes severe lung injury.Currently there are no effective protective strategies against radiation-induced lung injury (RILI).This study aimed to evaluate the ability of an angiogenesis antagonist, endostar, against RILI and the underlying mechanism in a mouse model.
其他文献
目的:探索低分子肝素在预防高危患者发生深静脉血栓中的作用.方法:对Caprini模型进行静脉血栓栓塞(VTE)评估为极高危(大于等于6分)的31例恶性肿瘤患者,在深静脉置管后进行预防性低分子肝素治疗,观察治疗前后D二聚体和血小板的变化,以及血栓发生率.结果:预防性低分子肝素治疗后的血栓发生率为9.7％ (3/31);血栓的发生与单因素(性别、年龄、吸烟、有无基础病、肿瘤类型、是否使用抗血管生成药物
Background: The measurement of the human epidermal growth factor receptor 2 (HER2) protein in the serum of metastatic breast cancer patients has now been reported, but there are no consistent data to
目的:目前,临床实践中运用荧光原位杂交技术(Fluorescence In Situ Hybridization,FISH)检测非小细胞肺癌ALK(anaplastic lymphoma kinase)基因的重排,以指导ALK抑制剂的应用.然而,由于FISH技术检测费用高、需要精密仪器设备,可能不适合大样本的人群筛查.本研究运用免疫组织化学法(Immunohistochemistry,IHC)检测
目的:观察注射用右丙亚胺预防应用表阿霉素治疗非霍奇金淋巴瘤患者后,出现心脏毒性的有效性和安全性.方法:20例初治的＜60岁的非霍奇金淋巴瘤患者,随机分为试验组与空白对照组,每组各10例,均接受至少4周期CHOP样方案的化疗,其中每周期表阿霉素(EPI) 80mg/m2,静脉滴注15分钟;试验组患者在EPI给药前30分钟接受注射用右丙亚胺800mg/m2,静脉滴注1小时.疗前、给药后1周及4周期化疗
背景及目的:随着高效低度药物的出现越来越多的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者有机会接受三线治疗,但目前三线的标准治疗除厄洛替尼外尚无其他选择方案.本研究旨在比较单药化疗、靶向药物与双药联合化疗在晚期NSCLC患者三线治疗中的疗效与安全性.方法:回顾分析115例Ⅲb期/Ⅳ期接受三线治疗的NSCLC患者的疗效及生存状况.采用Kaplan-Meie
目的:探讨EGFR基因启动子甲基化水平与人非小细胞肺癌细胞株H1650对吉非替尼敏感性之间的关系.方法:5-aza-CdR和吉非替尼单独或联合用药作用于H1650细胞株后,应用甲基化特异性PCR法检测EGFR基因启动子区甲基化状态;CCK-8法检测细胞增殖率;蛋白质印迹法和实时荧光定量PCR法检测EGFR蛋白和mRNA的表达情况.
Objective: The aim of this study was to investigate the relationship between the Methylenetetrahydrofolate reductase (MTHFR) C677T, excision repair cross-complementing group 1 (ERCC1) genetic polymorp
Background: Pancreatic cancer survival continues to be amongst the shortest of all cancers, and new therapies are urgently needed.In this study, we sought to identify the potential therapeutic effects
Esophageal carcinoma (EC) is a common malignancy and the major determinant of overall cancer mortality in Asia, with bone as one of the most frequent metastasic sites.The aim of this study was to esta
Using nanoparticle delivery for anticancer therapy is a potential new drug modality.We developed a novel pemetrexed-loaded PEG-Peptide-PCL nanoparticles.In this study, characterizations, drug loading